Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib, Camrelizumab, and Capecitabine in mCRC
NCT06148402Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, camrelizumab in colorectal cancer (CRC), sponsored by Sun Yat-sen Memorial Hospital. Started Nov 2023; status: recruiting.
02
Drugs
fruquintinibcamrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06148402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06148402.